Health Canada approves Bylvay (odevixibat) to treat pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis
Ipsen and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies to patients in international markets, are pleased to announce the Health Canada approval for Bylvay (odevixibat) for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC), a progressive and life-threatening liver disease
Bylvay is the first medication approved in Canada for the treatment of pruritus in patients aged six months or older with PFIC.
Medison and Ipsen are part of a multiregional partnership in both Canada and Israel to bring Bylvay, a highly innovative therapy for the treatment of pruritus due to PFIC, offering new hope for patients suffering from this rare disease, and their families.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.